Cardiovascular and immune system abnormalities have been reported in females with estrogen deficiency. To control these disorders in post-menopausal women, hormone replacement therapy (HRT) has been used. Tibolone has been used as a HRT, but the effects of tibolone on the natriuretic peptide system have not been determined. We investigated the effects of tibolone on the natriuretic peptide system and pro-inflammatory cytokines in ovariectomized (OVX) rats. Female rats were divided into four groups: SHAM, OVX, OVX treated with 17β-estradiol (OVX+E: 14 days) and OVX treated with tibolone (OVX+T: 14 days) beginning 21 days after ovariectomy. On day 35, blood was collected to determine atrial natriuretic peptide (ANP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) levels. In addition, tissues were collected for determining ANP, natriuretic peptide receptor type-A (NPR-A), and NPR type-C (NPR-C) gene expression levels by RT-PCR. The cytokine levels of both IL-6 and TNF-α were increased in OVX animals. In comparison, IL-6 and TNF-α levels were reduced in OVX+E animals. TNF-α levels were reduced similarly in OVX+T animals, but IL-6 levels remained elevated in this group. The concentrations of ANP in the left atrium tissue and plasma were decreased after ovariectomy, as were ANP mRNA levels in the left atrium and NPR-A mRNA levels in kidney. No variation in NPR-C gene expression in the kidney tissue was observed among the groups. Tibolone and 17β-estradiol effectively increased plasma ANP and ANP mRNA levels in the left atrium, but did not normalize renal NPR-A levels. Since HRT with tibolone normalizes plasma ANP and serum TNF-alpha levels our results suggest that treatment with tibolone has anti-inflammatory effects and could prevent cardiovascular disease in the long-term.
Introduction
Atrial natriuretic peptide (ANP) plays a vital role in regulating cardiovascular function, maintaining blood pressure and body fluid homeostasis [1] . In addition, inappropriate activation of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) has been recognized as an important mediator in the development of endothelial dysfunction, cardiac hypertrophy and heart failure in experimental animal models and humans [2] [3] [4] . Evidence from human and animal studies shows that a decrease of estrogen levels is accompanied by inhibition of ANP gene expression [5] [6] [7] , diminished circulating levels of ANP [6] [7] [8] [9] [10] , and increased production of pro-inflammatory cytokines such as IL-6 and TNF-α [11] [12] [13] [14] . Thus, the impairment of the immune system and the cardiovascular system observed with estradiol deficiency may be associated.
Indeed, recent studies have begun to elucidate the influence of ANP on the immune system [15] [16] [17] . In mice lacking natriuretic peptide receptor type A (NPR-A), enhanced activation of pro-inflammatory cytokines is detected [18] . NPR-A has guanylate cyclase activity and mediates the majority of the biological effects of ANP [19] . In addition, ANP binds natriuretic peptide receptor type-C (NPR-C), which does not have guanylate cyclase activity, but removes natriuretic peptides from circulation [20] and is abundantly expressed in the kidney [21] . Further supporting a link between ANP and the immune system, ANP and its receptors are expressed by, and regulated by, immune cells [16] .
Few studies have investigated the effects of hormone replacement therapy (HRT) with estrogen on ANP and, to our knowledge, there are no data available concerning the effect of tibolone on the natriuretic peptide system. Tibolone, which has metabolites with estrogenic Regulatory Peptides 179 (2012) [55] [56] [57] [58] [59] [60] effects (3alpha-hydroxy tibolone [3α-OH] and 3beta-hydroxy tibolone [3β-OH]) and progestogenic and/or androgenic effects (tibolone and Delta(4)tibolone), may be used as an alternative to classical HRT with estrogen and progesterone [22] [23] [24] . In order to further elucidate the effects of the tibolone, we examined how tibolone treatment affects the natriuretic peptide system in rats. We hypothesized that tibolone treatment would alter ANP synthesis, secretion, and bioavailability in circulation and that a tibolone treatment that has the aforementioned effects on the natriuretic peptide system may also affect levels of inflammatory cytokines, such as TNF-α and IL-6, in ovariectomized rats.
Accordingly, this study was designed to evaluate whether tibolone treatment can normalize the natriuretic peptide system and promote a reduction in the levels of TNF-α and IL-6 in ovariectomized rats.
Materials and methods

Animals
Adult female Wistar rats weighing 160-180 g were obtained from the breeding unit at the Federal University of Espírito Santo. The rats were housed with controlled temperature (22°C), humidity (40%) and light cycles (12-h light/dark), and they were given water and standard rat chow (Purina Labina, SP-Brazil) ad libitum. The procedures were carried out in compliance with the guidelines for the ethical use of animals in scientific research as stated by the Federation of the Brazilian Society of Experimental Biology and were approved by the Ethics Committee for Animal Use at the Federal University of Espírito Santo (014/2008). Ketamine (70 mg/kg) and xylazine (10 mg/kg) were injected intraperitoneally to anesthetize the rats prior to all surgical procedures.
Four groups of female rats were studied: sham-operated females (SHAM); ovariectomized (OVX); OVX treated with 17β-estradiol (OVX+E: 0.5 μg/kg/day; Sigma Chemical Co., St. Louis, MO, USA) or OVX treated with tibolone (OVX+T: 1.5 mg/kg/day). Tibolone was given by gavage, and 17β-estradiol was injected subcutaneously. The rats were treated for 14 days beginning 21 days after bilateral ovariectomy.
Measurement of arterial blood pressure (BP) and heart rate (HR)
Mean arterial pressure and heart rate were determined by direct measurement in each group at the end of treatment. Forty-eight hours after the end of the treatment, BP and HR at rest were measured. For this procedure, on the day before the measurement was taken, a catheter filled with saline (PE-50) was inserted into the left femoral artery while the subject was under anesthesia (ketamine 70 mg/kg, xylazine 10 mg/kg). The free end of the catheter was exteriorized at the cervical dorsal area. For the BP measurement, the arterial catheter was attached to a 40-cm polyethylene catheter during the 40 min recording period. BP measurements were obtained in quiet, conscious rats that had complete freedom to move throughout the cage. The BP was recorded by a pressure transducer coupled to a MP-100 System Guide (model MP100-CE; Biopac Systems, Santa Barbara, CA, USA). The HR was calculated instantaneously from the intervals of pressure pulses.
Collection of serum, plasma and tissues
After measuring BP and HR, the females were decapitated, and 5 ml of blood was collected in pre-chilled tubes containing heparin sulfate and protease inhibitors: 10 , to obtain plasma. Blood samples were also collected in empty tubes to obtain serum. The blood samples were centrifuged at 4°C and 2500 rpm (Eppendorf, Hamburg, Germany) for 15 min. Plasma and serum were stored at −80°C. The uterus, atrium, ventricle and kidneys were removed, weighed, frozen in liquid nitrogen and stored at − 80°C.
Levels of cytokines and ANP
The levels of IL-6 and TNF-α in serum were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions (Invitrogen-BioSource International).
The level of ANP was determined by performing a doubleantibody radioimmunoassay (RIA) as described by Gutkowska et al. [25] . The plasma was thawed and centrifuged for 5 min at 19,400 ×g and 4°C, and ANP was extracted using Sep-Pak C18 columns (Waters Associates, Milford, MA, USA). The columns were activated with 8 ml of acetonitrile and washed with 8 ml of 0.2% ammonium acetate, pH 4.0. Afterward, 1 ml of plasma was infused into the column followed by 5 ml of 0.2% ammonium acetate. Finally, the absorbed ANP was eluted with 3 ml of 60% acetonitrile in 0.2% ammonium acetate, evaporated (Speed-Vac, Eppendorf, Hamburg, Germany) and stored at −20°C for quantification by RIA.
To 14 mmol/l bovine serum albumin, 0.1% Triton X-100, 0.1 mol/l NaCl and 0.01% sodium azide at pH 7.4). The ANP levels were measured by RIA as previously described by Gutkowska et al. [25] using a specific antibody that was donated by Jolanta Gutkowska. All of the samples were measured in the same assay, and the intra-assay coefficient of variation was b 10%. The protein content of the tissue was determined using the Bradford method [26] .
Gene expression of ANP, NPR-A and NPR-C
Total mRNA was extracted from the atria and kidneys by a guanidine isothiocyanate method previously described by Chomczynski and Sacchi [27] . The mRNA expression levels of ANP and its receptors (NPR-A and NPR-C) were determined by real-time PCR. The gene expression of ANP was evaluated in the RA and LA, and NPR-A and NPR-C expression levels were determined in the right kidney. cDNA was synthesized by the reverse transcription of mRNA. For this process, 1 μl of mRNA from each sample was mixed in plastic tubes with a solution containing the following compounds: diethyl pyrocarbonate water (DEPC), the reverse primer of the target gene (ANP, NPR-A or NPR-C) or the reverse primer of the housekeeping gene (ribosomal subunit s26), oligo dT, triphosphate deoxyribonucleotide (dNTP), dithiothreitol (DTT), specific buffer (10 ×) and a solution containing the Moloney murine leukemia virus (MMLV) reverse transcriptase enzyme, according to the manufacturer's guidelines (Invitrogen, CA, USA). After this process, the plastic tubes were heated to 40°C for 60 min. After reaching room temperature, the tubes were stored at − 20°C.
For the atria, the samples were subjected to DNAse treatment prior to reverse transcription. The DNase treatment was performed by mixing 0.5 μg of total mRNA from the atria with 4 μl of water and 1 μl of buffer containing DNAse (1:1). This mixture was incubated for 15 min at room temperature. After the incubation period, EDTA was added to stop the reaction. The samples were then heated to 65°C for 10 min.
After synthesizing the cDNA, PCR was performed to amplify the cDNA for ANP, NPR-A and NPR-C, using specific primers (ANP: 5′-GGA TTT CAA GAA CCT GCT AGA-3′ and 5′-CTT CAT CGG TCT GCT CGC TCA-3′; NPR-A: 5′-ATC ACA GTG AAT CAC CAG GAG TTC-3′ and 5′-AGA TGT AGA TAA CTC TGC CCT TTC G-3′; NPR-C: 5′-CCT ACA ATT TCG ACG AGA CCA AA-3′ and 5′-ACT CGC TCA CTG CCC TGG ATG TA-3′).
For this procedure, 2 μl of cDNA was added to wells of real-time PCR plates, followed by 1.5 μl of sense primer (1 pmol/μl), 1. 
Data analysis
Data are expressed as the mean ± standard error of mean (SEM), and the statistical analysis was performed using GraphPad Prism 5. Data were compared using one-way ANOVA followed by NewmanKeuls post hoc test. Data were considered statistically significant if P b 0.05.
Results
3.
1. The effects of OVX and tibolone on physiological parameters, blood pressure and heart rate Baseline physiological parameters in SHAM and OVX animals and the effects of HRT are reported in Table 1 . Ovariectomy led to increased body weight (BW); however, the treatment with 17β-estradiol (OVX+E) or tibolone (OVX+T) normalized BW (P b 0.01). The uterus weight as well as the uterus weight-to-BW ratio were largely decreased in the OVX groups (P b 0.01) indicating the efficiency of ovariectomy. However, in the OVX+T group, there was an increase in the uterus weight-to-BW ratio compared to the OVX group, but did not return to normal when compared to the SHAM group. This finding is different from what occur in the OVX+E group when the uterus weight-to-BW ratio returned to normal values. Ovariectomy or any of the HRT used in the present study did not alter the weight-to-BW ratio of the heart chambers ( Table 1) .
Mean arterial pressure (MAP) and heart rate (HR) were not different in the SHAM and OVX groups (105± 2 vs. 98± 1 mmHg and 373± 7 vs. 372 ±6 beats per min, respectively). In addition, administration of 17β-estradiol or tibolone, respectively, to ovariectomized rats did not change MAP (101± 2 and 103 ± 3 mmHg) or HR (368±5 and 364 ± 9 beats per min).
Levels of ANP and NPR in response to ovariectomy and 17β-estradiol or tibolone treatment
In the vehicle-treated OVX rats, the plasma ANP concentrations (92.50 ± 19.50 pg/ml) were lower than in the SHAM group (263.30 ± 53.30 pg/ml, P b 0.05). Treatment with 17β-estradiol or tibolone increased plasma levels of ANP in OVX rats (OVX+E: 247.30 ± 29.90; OVX+T: 285.70 ± 60.40 pg/ml, P b 0.05 vs. OVX) (Fig. 1) .
RIA revealed that ovariectomy and estradiol treatment decreased and increased ANP concentrations, respectively, in the left atrium but not the right atrium (Fig. 2A) . The ANP concentration in the left atrium decreased from 5.68 ± 0.35 μg/mg protein in the SHAM group to 3.48 ± 0.40 μg/mg protein in the OVX group (P b 0.05). However, in the OVX+E group, the ANP levels in the left atrium increased to 6.48 ± 0.97 mg/mg protein (P b 0.05), which was similar to the levels observed in the SHAM group. On the other hand, the ANP levels in the left atrium did not return to levels similar to the SHAM group in the OVX+T group (3.59 ± 0.25 mg/mg protein, P b 0.05 vs. SHAM). As shown in Fig. 2B , changes in the ANP mRNA levels were associated with increased plasma ANP levels. The OVX group had lower ANP mRNA levels in the left atrium (40.00 ± 10.10 AU) compared with the SHAM group (91.30 ± 4.40) indicating that lower levels of ANP synthesis were occurring in the OVX group. 17β-estradiol or tibolone treatment induced a large increase in the ANP gene expression in the left atrium of ovariectomized rats (OVX+E: 122.30 ± 12.00; OVX+T: 167.90 ± 25.70 AU, P b 0.01 vs. OVX). Changes in ANP receptor expression in the kidney tissues were compared using RT-PCR. The kidneys from the ovariectomized rats had lower NPR-A mRNA expression (0.68 ± 0.11 AU) compared to the SHAM group (12.00 ± 5.20 AU). On the other hand, neither 17β-estradiol nor tibolone treatment normalized the expression of NPR-A in the ovariectomized females (OVX+E: 0.92 ± 0.28 and OVX+T: 2.04 ± 1.04 AU) (Fig. 3A) . No variation in NPR-C gene expression in the kidney tissue was observed among the groups (Fig. 3B). 3.3. Pro-inflammatory cytokine levels in response to ovariectomy and 17β-Estradiol or tibolone treatment Fig. 4 shows the average level of IL-6 (A) and TNF-α (B) in the serum of rats from every group. Ovariectomy resulted in a significant elevation of IL-6 and TNF-α levels (IL-6: 32.80 ± 5.00 and TNF-α: 31.00 ± 5.00 pg/ml) compared with the SHAM group (IL-6: 19.30 ± 6.00 and TNF-α: 20.30 ± 2.00 pg/ml). Treatment with 17β-estradiol decreased the IL-6 and TNF-α levels in the serum of the ovariectomized rats (IL-6: 20.00 ± 3.00 and TNF-α: 17.60 ± 2.00 pg/ml, P b 0.01 vs. SHAM). However, tibolone treatment in the ovariectomized rats (OVX+T) decreased TNF-α levels but not IL-6 levels (34.40 ± 2.80) in the serum compared to the OVX group (17.60 ± 2.00 pg/ml, P b 0.01 vs. OVX).
Discussion
Tibolone may be useful as an alternative to classical HRT with estrogen and progesterone. However, the effects of tibolone on the natriuretic peptide system have not been elucidated. The present study demonstrated that decreased ANP levels in estrogen-deficient female rats were accompanied by an increase in circulating levels of IL-6 and TNF-α. Plasma ANP levels were increased and serum TNF-α levels were decreased in tibolone treated OVX rats. Although ANP is a hormone that promotes acute vasodilation, natriuresis, and diuresis, with a consequent reduction in blood pressure [28] , the reduction in plasma levels of ANP in OVX females in our study did not lead to hemodynamic changes 35 d after estrogen deprivation. Previous studies have shown that, in both women and animals, HRT with estradiol caused plasma ANP levels to rise while BP values remained unchanged [6, 9, 10, 29] . The role of ANP is more evident when there is hypertension. HRT with 17β-estradiol has been reported to reduce BP in spontaneously hypertensive rats, with a concomitant increase in the synthesis and release of ANP, suggesting that the natriuretic peptide system is modulated by 17β-estradiol [10] .
In the current study, ovariectomy led to a reduction in plasma ANP concentrations and renal NPR-A mRNA levels, without affecting the expression of NPR-C. The lower level of plasma ANP observed in OVX rats in the absence of a change in NPR-C clearance receptors suggests that ANP synthesis was impaired in the OVX group. Tibolone treatment induced a large increase in ANP gene expression in the left atrium as well as a large increase in plasma ANP levels in OVX rats. However, the ANP levels in the left atrium were not normalized by the tibolone treatment. Given that androgens have previously been shown to increase ANP release [30] , a likely mechanism of action of tibolone is that an androgen metabolite of tibolone is responsible for the increases in ANP levels observed in our tibolone treated rats. Our data also suggest that tibolone itself can induce ANP release, because tibolone treatment did not normalize ANP concentration in the left atrium. The effects of tibolone on the formation of the atrial granules and on the secretion of ANP need to be elucidated.
Our findings with respect to ANP receptor expression in the kidney demonstrated that tibolone treatment did not normalize renal NPR-A mRNA levels in OVX animals, while the increased plasma ANP levels that were observed could potentially lead to an improvement in ANP biological activity, since NPR-A is expressed in other tissues, such as adipose tissues [7] and immune cells [16] . Thus, we believe that ANP synthesis was normalized in our OVX+T group due an increase ANP mRNA and plasma ANP levels without a change in renal clearance receptors. If neutral endopeptidase 24.11 (NEP) [31] is involved in ANP degradation, it could potentially play a role in the increased ANP observed in tibolone-and 17β-estradiol-treated rats. However, this possibility is sustained by a prior study reporting that estrogen did not significantly affect NEP activity in the renal cortex and medulla of female rats [32] .
Our results also showed that OVX females had increased serum levels of pro-inflammatory cytokines (IL-6 and TNF-α) and low plasma levels of ANP. Few studies have examined the actions of tibolone on the immune system, and the information we do have regarding the influence of this drug on pro-inflammatory cytokines is conflicting. One study showed that HRT with tibolone for 2 months in postmenopausal women did not decrease TNF-α, IL-4, IL-10, or IL-2 levels, though it did reduce bone resorption [12] . In contrast, another study reported that tibolone had a beneficial effect on inflammation in post-menopausal women, reducing TNF-α levels but not IL-6 levels [33] . Here, we also found that tibolone reduced TNF-α levels without affecting serum levels of IL-6 in female rats, whereas estrogen reduced the levels of both cytokines. We further speculate that plasma ANP, in addition to its known cardiovascular effects, may also normalize levels of pro-inflammatory cytokines. Our observations are consistent with previous reports indicating that ANP-induced cyclic GMP signaling can suppress the release TNF-α in vitro [16, 34] and in vivo [17, 35] via inhibition of NF-kβ activity.
The differing responses induced by tibolone versus estrogen in our study may be attributable to tibolone metabolites acting on other receptors [22] [23] [24] , in addition to the estrogen receptor. Tibolone's three main metabolites, 3α-hydroxytibolone, 3β-hydroxytibolone, and the Delta(4)tibolone isomer, possess different affinities. The hydroxytibolone metabolites bind to estrogen receptors, triggering estrogen-like responses, whereas the Delta(4)tibolone isomer has a high affinity for progesterone and androgen receptors (22) . Therefore, relative to estrogen which binds selectively to estrogen receptors, tibolone may produce more complex effects via the actions of at least one of its metabolites on these other receptors.
In conclusion, the present study demonstrated that estrogen deficiency in OVX rats impaired the natriuretic peptide system, which may have contributed to the elevated concentrations of inflammatory cytokines observed in this experimental model. We showed for the first time the influence of tibolone on the natriuretic peptide system in OVX rats. Our experiments demonstrated that tibolone possesses anti-inflammatory actions in vivo, as evidenced by increased ANP levels and decreased TNF-α levels. These findings may have important implications for the treatment of post-menopausal cardiovascular and immunological complications.
